Given their efficacy in addressing hyperglycemia, hyperinsulinemia, and excess adipose tissue, GLP-1 based therapies are potentially valuable in preventing and mitigating obesity-related kidney disease. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.